IGC Pharma (FRA:IGS1) Long-Term Capital Lease Obligation : €0.01 Mil (As of Dec. 2024)

View and export this data going back to 2010. Start your Free Trial

What is IGC Pharma Long-Term Capital Lease Obligation?

IGC Pharma's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.01 Mil.

IGC Pharma's quarterly Long-Term Capital Lease Obligation declined from Jun. 2024 (€0.06 Mil) to Sep. 2024 (€0.03 Mil) and declined from Sep. 2024 (€0.03 Mil) to Dec. 2024 (€0.01 Mil).

IGC Pharma's annual Long-Term Capital Lease Obligation declined from Mar. 2022 (€0.31 Mil) to Mar. 2023 (€0.19 Mil) and declined from Mar. 2023 (€0.19 Mil) to Mar. 2024 (€0.08 Mil).

IGC Pharma Long-Term Capital Lease Obligation Historical Data

The historical data trend for IGC Pharma's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGC Pharma Long-Term Capital Lease Obligation Chart

IGC Pharma Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.44

0.34

0.31

0.19

0.08

IGC Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.11	0.08	0.06	0.03	0.01

IGC Pharma (FRA:IGS1) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

IGC Pharma Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of IGC Pharma's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

IGC Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGC Pharma Inc (FRA:IGS1) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

IGC:USA

Address

10224 Falls Road, Potomac, MD, USA, 20854

Website

https://www.igcinc.us

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

IGC Pharma Headlines

No Headlines